Skip to content
OpenCapital
Get started

Alamar Biosciences ALMR Loss On Remeasurement Of Convertible Notes

Other financials

Income statement

See full
Revenue$26.0M+98.9%
Gross profit$14.5M+126%
Operating income-$12.3M-44.4%
Net income-$21.3M-178%
EPS (diluted)-$1.74-156%

Balance sheet

See full
Cash & equivalents$64.6M—
Total debt$30.6M—
Total equity-$178.1M—
Total assets$186.5M—

Cash flow

See full
Operating cash flow-$20.3M-55.7%
CapEx$600.0K+8.3%
Free cash flow-$20.9M-53.8%

Valuation

See full
Market cap$1.52B—
Enterprise value$1.49B—

Returns & leverage

See full
Debt / equity-0.2×—
Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept ck0002104204:LossOnRemeasurementOfConvertibleNotes.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's loss on remeasurement of convertible notes.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alamar Biosciences 's loss on remeasurement of convertible notes?
Alamar Biosciences (ALMR) reported loss on remeasurement of convertible notes of $8.59M in Q1 2026.